BREAKING WITH
BLOCKBUSTERS
The great challenge for pharma and biotech
companies is to keep their pipeline brimming with promising new drugs. Will Ollard discovers how the
big companies intend to do so in the future.
more..
|
SUCCESS:
SWISS STYLE
In light of the current measuring of pharma and biotech forces, one
biotech company stands out among the others: Serono. Will Ollard speaks to Stuart Grant, Serono’s CFO, about the company’s unique profile. more.. |
BUILDING BIOTECH BRIDGES
Scandinavia is joining forces to jump on the biotech bandwagon. Various cross-border scientific groups are beating international competition with innovative research methods. World Pharmaceutical Frontiers takes a close look at the region. more.. |
PAT POINTS PHARMA TO IT
Traditional approaches to regulating quality in pharmaceutical manufacturing have led to product rejection, recalls and limited adoption of new manufacturing technologies. PAT wants to change all that, says David Rudd, GSK representative within CPACT. more..
Read more on 'Manufacturing' by key suppliers |
THE EMERGENCE OF
VIRTUAL SCREENING
High throughput screening of large collections of chemical compounds remains an important step in many drug discovery research projects. Jin Li and Timothy Lovell, Chemical Computing, AstraZeneca, review the complementary virtual screening methodologies. more..
Read more on 'Drug Discovery & Development' by key suppliers |
ECOSYSTEMS FOR FUTURE SUCCESS
All industries experience life cycles, and the pharma industry is no exception. Chemistry-based medical innovations of the twentieth century are beginning to decline in importance. more.. |
BIOTECH KEY DRIVER OF PHARMACEUTICAL GROWTH
Over the last five years, the biotech industry has endured a number of significant challenges, notably in technology, market dynamics and regulations. Despite this, the sector strengthened in 2004, a trend that is expected to continue until 2010. Guy Bate
and Eva Edery of IMS Management Consulting take a look at biotech’s promising future. more.. |
PATENTS,ROYALTY
STACKING AND MANAGEMENT
Dr Raju Adhikari, industry manager of Pharmaceutical and Biotechnology, Frost &
Sullivan discusses the many issues concerning
the protection of intellectual property rights. more..
Read more on 'Regulatory & Legal Update' by key suppliers |
MES: GETTING IT TOGETHER
Ralph Haefeli, of Novartis Pharma AG, presents a case study that illustrates how integrated MES
solutions contribute to operational excellence. more..
Read more on 'Manufacturing' by key suppliers |
IS THERE A MUX UP?
Nicholas Westwood, University of St
Andrews, and Graham Smith, Pfizer Global
R&D, discuss the technology associated
with the analysis of crude reaction mixtures. more..
Read more on 'Drug Discovery & Development' by key suppliers |
EXCIPIENTS IN THE
SPOTLIGHT
With public awareness of additives higher than ever before, the development of chemicals and excipients, and of standards to monitor their safety, is a top priority, writes SOCMA president Joseph Acker. more..
|
GLOBAL ALLIANCE
DEVELOPMENT
Alliances are becoming more common in the
pharmaceuticals industry. The Global Discovery Alliances team at AstraZeneca reveal the merits such ventures have
in contributing to the success of a company’s business strategy. more..
Read more on 'Drug Delivery' by key suppliers
|
|
STANDARDS SET TO TAKE OFF
With data sharing becoming a frequent procedure, especially in light of the continuing
increase of outsourcing, standards are essential. Implementation is moving slowly, but
the time is now, explains the Clinical Data Inter change Standards Consortium. more.. |
COMBATING THE
COUNTERFEITERS
The amount of fake drugs in the supply chain is increasing, as the opportunity for
financial gain blinds some to the potentially devastating consequences for patient safety. If the problem goes unchecked, more than profits will be at stake. more..
Read more on 'Packaging' by key suppliers |
